Cargando…

Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir

Detalles Bibliográficos
Autores principales:	Bai, Yu, Ye, Fei, Feng, Yong, Liao, Hanyi, Song, Hao, Qi, Jianxun, Gao, George Fu, Tan, Wenjie, Fu, Lifeng, Shi, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7860160/ https://www.ncbi.nlm.nih.gov/pubmed/33542181 http://dx.doi.org/10.1038/s41392-021-00468-9

Ejemplares similares

Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease
por: Kneller, Daniel W., et al.
Publicado: (2022)

Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease
por: Fu, Lifeng, et al.
Publicado: (2020)

Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease: room-temperature X-ray and neutron crystallography, binding thermodynamics, and antiviral activity
por: Kneller, Daniel, et al.
Publicado: (2022)

Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease
por: Mengist, Hylemariam Mihiretie, et al.
Publicado: (2021)

Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir
por: Peng, Qi, et al.
Publicado: (2021)

Pharmacokinetics of the New Hepatitis C Virus NS3 Protease Inhibitor Narlaprevir following Single-Dose Use with or without Ritonavir in Patients with Liver Cirrhosis
por: Isakov, V., et al.
Publicado: (2016)

Structure of SARS-CoV-2 main protease in the apo state
por: Zhou, Xuelan, et al.
Publicado: (2020)

Protein structural heterogeneity: A hypothesis for the basis of proteolytic recognition by the main protease of SARS-CoV and SARS-CoV-2
por: Behnam, Mira A.M.
Publicado: (2021)

Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2
por: Zhao, Yao, et al.
Publicado: (2022)

Activation and maturation of SARS-CoV main protease
por: Xia, Bin, et al.
Publicado: (2011)

Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332
por: Li, Jian, et al.
Publicado: (2022)

Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease
por: Noske, Gabriela Dias, et al.
Publicado: (2023)

The SARS-CoV-2 main protease as drug target
por: Ullrich, Sven, et al.
Publicado: (2020)

Topological analysis of SARS CoV-2 main protease
por: Estrada, Ernesto
Publicado: (2020)

Potential SARS-CoV-2 main protease inhibitors
por: Banerjee, Riddhidev, et al.
Publicado: (2021)

Developing inhibitors of the SARS-CoV-2 main protease
por: Seitz, Christian, et al.
Publicado: (2022)

Allosteric Hotspots in the Main Protease of SARS-CoV-2
por: Strömich, Léonie, et al.
Publicado: (2022)

Allosteric inhibitors of the main protease of SARS-CoV-2
por: Samrat, Subodh Kumar, et al.
Publicado: (2022)

Impact of Drug Repurposing on SARS-Cov-2 Main Protease
por: Ndagi, Umar, et al.
Publicado: (2023)

Reply to Yan et al.: Quercetin possesses a fluorescence quenching effect but is a weak inhibitor against SARS-CoV-2 main protease
por: Xu, Haiyu, et al.
Publicado: (2023)

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
por: Zhang, Linlin, et al.
Publicado: (2020)

Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2′s main protease
por: Mahdi, Mohamed, et al.
Publicado: (2020)

Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL(pro)
por: Ma, Ling, et al.
Publicado: (2022)

Biochemical screening for SARS-CoV-2 main protease inhibitors
por: Coelho, Camila, et al.
Publicado: (2020)

Correlation between dissociation and catalysis of SARS-CoV main protease
por: Lin, Pei-Ying, et al.
Publicado: (2008)

Copper(II) Inhibition of the SARS-CoV-2 Main Protease
por: Garza-López, Roberto A., et al.
Publicado: (2020)

Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors
por: Huff, Sarah, et al.
Publicado: (2021)

Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease
por: Katagishi, Daiki, et al.
Publicado: (2023)

Optimization of the expression of the main protease from SARS-CoV-2
por: Rong, Yi, et al.
Publicado: (2023)

Potent and biostable inhibitors of the main protease of SARS-CoV-2
por: Tsuji, Kohei, et al.
Publicado: (2022)

Insights into the structural properties of SARS-CoV-2 main protease
por: Akbayrak, Ibrahim Yagiz, et al.
Publicado: (2022)

Dynamics of the SARS-CoV-2 main protease binding site
por: Harith, Advaith S., et al.
Publicado: (2023)

Effect of chitooligosaccharide on the inhibition of SARS-CoV-2 main protease
por: Wang, Qian, et al.
Publicado: (2023)

Characterization of host substrates of SARS-CoV-2 main protease
por: Melano, Ivonne, et al.
Publicado: (2023)

The molecular basis for SARS-CoV-2 binding to dog ACE2
por: Zhang, Zengyuan, et al.
Publicado: (2021)

Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays
por: Ma, Chunlong, et al.
Publicado: (2022)

Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332
por: Zhao, Yao, et al.
Publicado: (2021)

Insect protease inhibitors; promising inhibitory compounds against SARS-CoV-2 main protease
por: Hemmati, Seyed Ali, et al.
Publicado: (2022)

High-throughput screening and evaluation of repurposed drugs targeting the SARS-CoV-2 main protease
por: Li, Yan, et al.
Publicado: (2021)

Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease
por: Douangamath, Alice, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lflidmu5ktrr3lfbhnmb9kjtkg